Paula Brown Stafford joins Allucent in a planned leadership transition, bringing 35+ years of life science experience, including with Quintiles and Novan, Inc., to guide company's next phase of growth Mark A. Goldberg, M.
D., who spearheaded Allucent's transformation to a global CRO serving small and mid-sized biopharmaceutical companies, will continue to serve as chairman CARY, N.C.
, July 23, 2024 /PRNewswire/ -- Allucent today announced that it has appointed industry veteran Paula Brown Stafford as chief executive officer to advance the next phase of its expansion. Ms. Stafford succeeds Mark A.
Goldberg , M.D. , in a planned transition following his leadership in building Allucent into a global clinical research organization (CRO) uniquely positioned to serve small and mid-sized biopharmaceutical businesses.
Ms. Stafford brings to Allucent more than 35 years of industry experience. At Quintiles (now IQVIA), she played a key role in growing its CRO services.
As president of the global life science provider's largest business unit, she led 22,000 employees across 60 countries in delivering Phase I-IV clinical research services. Ms. Stafford also was president, CEO and chairman of Novan, Inc.
, a clinical development-stage biotechnology company. Dr. Goldberg, who will continue to serve as chairman of Allucent's board of directors, stated: "Paula is known for her dynamic leadership and unwavering commitment to helping deliver needed therapies to patients.
Having held key positio.